|Videos|November 4, 2017

Providers: Be Assertive When Recommending Flu Vaccination to Older Adults

William Schaffner, MD, explains how health care providers can work towards getting patients who are aged 65 and older to receive a flu shot.

William Schaffner, MD, medical director for the National Foundation for Infectious Diseases’ (NFID) and infectious disease physician at Vanderbilt, explains how health care providers can work towards getting patients who are aged 65 and older to receive a flu shot.

Interview Transcript (modified slightly for readability):

[So, what about] the role of the provider, and physicians for sure, but also pharmacists, and everyone else who deals with the public? It is said that we should recommend influenza vaccine to everyone because the recommendations say that everyone older than 6 months of age should be vaccinated each and every year against influenza.

But a recommendation can be made very casually. ‘Oh, Tom, it’s that time of the year. You ought to think about getting your flu vaccine.’ That’s a recommendation? That’s giving the patient permission to decline vaccination. We don’t say that about the treatment of diabetes. ‘Oh, you ought to think about getting your diabetes treated, Tom.’

We need to insist on vaccination. We need to say, ‘It’s that time of the year; we vaccinate everyone in our practice.’ And if you get pushback, look at the patient in a kind of an alarmed way and say, ‘I’ve been vaccinated. My whole family has been vaccinated. Everybody in the office has been vaccinated. Tom, we’re going to vaccinate you before you go home.’ Because it’s so important to do everything we can to prevent influenza, and if we are more assertive rather than just casually recommending, I think we’ll vaccinate many, many more people.

You’d be surprised how many people have a health care encounter during the fall and leave the doctor’s office, the pharmacy, or wherever, unvaccinated. That shouldn’t happen.”


Related to this article

GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.